Lv54
810 积分 2021-08-12 加入
KRASG12C inhibitor combination therapy in metastatic non-small-cell lung cancer: choosing the right path
1天前
已完结
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
1天前
已完结
Discovery of Clinical Candidate IAG933, a Potent YAP-TEAD PPI Disrupter
3天前
已完结
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
4天前
已完结
Autophagolysosomal exocytosis inverts Src kinase onto the cell surface in cancer
17天前
已完结
Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma
20天前
已完结
YAP Induces a Prorenewal Metabolic State in Cardiomyocytes
23天前
已完结
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors
1个月前
已完结
Discovery and In Vivo Evaluation of Aryl Ether YAP1/TEAD Inhibitors for the Treatment of Hippo-Driven Malignancies
1个月前
已完结
Kras G12C– and G12D–driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models
1个月前
已完结
皖公网安备34019202002308
